A randomized, subject and investigator blinded, placebo controlled, multi-center study in parallel groups to assess the efficacy and safety of CJM112 in patients with moderate to severe inflammatory acne
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2017
At a glance
- Drugs CJM 112 (Primary)
- Indications Acne; Acne vulgaris
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 25 Jul 2017 Planned End Date changed from 26 Oct 2018 to 10 Jan 2019.
- 25 Jul 2017 Planned primary completion date changed from 26 Oct 2018 to 10 Jan 2019.
- 14 Mar 2017 Planned number of patients changed from 90 to 75.